S-Space College of Medicine/School of Medicine (의과대학/대학원) Molecular and Clinical Oncology (분자종양의학전공) Journal Papers (저널논문_분자종양의학전공)
Retrospective analysis of peripheral blood stem cell transplantation for the treatment of high-risk neuroblastoma
- Kim, Eun Kyung; Kang, Hyoung Jin; Park, Jeong Ah; Choi, Hyoung Soo; Shin, Hee Young; Ahn, Hyo Seop
- Issue Date
- Korean Academy of Medical Science
- J Korean Med Sci. 2007 Sep;22 Suppl:S66-72.
- Antigens, CD34/metabolism; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Infant; Korea/epidemiology; Male; Neuroblastoma/mortality/*therapy; Peripheral Blood Stem Cell Transplantation/adverse effects/mortality; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous
- Disease relapse after autologous peripheral blood stem cell transplantation (APBSCT) is the main cause of treatment failure in high-risk neuroblastoma (NBL). To reduce relapse, various efforts have been made such as CD34+ selection and double APBSCT. Here the authors reviewed the clinical features and outcomes of highrisk NBL patients and analyzed their survival. The medical records of 36 patients with stage III or IV NBL who underwent APBSCT at Seoul National University Children's Hospital between May 1996 and May 2004 were reviewed. Total 46 APBSCTs were performed in 36 patients. Disease free survival (DFS) and overall survival of all patients were 47.7% and 68.8%, respectively. The patients were allocated to three groups according to the APBSCT type. The DFS of CD34+ non-selected single APBSCT patients (N=13), CD34+ selected single APBSCT patients (N=14), and CD34+ selected double APBSCT patients (N=9) were 55.6%, 40.6%, and 50.0%, respectively, which were not significantly different. Thus the survival was not found to be affected by CD34+ selection or transplantation number. To improve long-term survival, various efforts should be made such as chemotherapy dose intensification, more effective tumor purging, and control of minimal residual disease via the use of differentiating and immune-modulating agents.
- 1011-8934 (Print)